ArticleTherapeutic advances in gastroenterology2026
Predictability of peripheral blood inflammatory markers in prediction of lymph node metastasis in gastric cancer.
Article in Therapeutic advances in gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) has high incidence and mortality rates worldwide, and lymph node metastasis (LNM) is a key determinant of prognosis and treatment strategy. Objectives: In this study, we aimed to investigate the association between eight inflammatory markers and LNM in GC and develop a prognostic model for LNM using inflammatory indicators. Design: This was a retrospective multicenter study. Methods: Clinical, pathological, and laboratory data from 868 GC patients were analyzed. Independent risk factors for LNM were identified through univariate logistic regression (LR), least absolute shrinkage and selection operator regression, and multivariable LR. Fourteen machine learning models were constructed using 10-fold cross-validation, and model performance was evaluated by calculation of the area under the receiver operating curve (AUC). Results: Five clinical and pathological characteristics were identified as independent risk factors for LNM in GC: Glasgow prognostic score (GPS), T stage, histological differentiation, vascular invasion, and total lymph node count. The categorical boosting (CatBoost) model demonstrated the best performance (AUC: 0.808) of all machine learning models tested, followed by the random forest model (0.806). Conversely, the AdaBoost model had the lowest AUC score (0.727). Further analysis of the CatBoost model showed that at the optimal threshold (0.56), it correctly identified approximately 82.7% of patients with LNM and approximately 69.4% of LNM-negative patients. Conclusion: These findings demonstrate the value of inflammatory markers, including the GPS, in prediction of LNM in patients with GC, as well as the ability of machine learning models to enhance prognostic accuracy, support informed treatment decisions, and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.